Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
28 hedge funds and large institutions have $3.97M invested in Regulus Therapeutics in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
17% more funds holding
Funds holding: 24 → 28 (+4)
0.68% more ownership
Funds ownership: 3.42% → 4.1% (+0.68%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
38% less capital invested
Capital invested by funds: $6.37M → $3.97M (-$2.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.65M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$61.6K |
| 3 |
Renaissance Technologies
New York
|
+$34.4K |
| 4 |
MIG
McGuire Investment Group
Wakefield,
Rhode Island
|
+$16.6K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$386K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$92.3K |
| 3 |
Rockefeller Capital Management
New York
|
-$22K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$105 |
RGLS Hedge Fund Activity: Q1 2020 in Review
28 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2020, worth a combined $3.97M — down 38% from $6.37M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RGLS positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.65M. The largest seller was BVF Inc, cutting an estimated $386K.
- 28 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2020, up from 24 in Q4 2019.
- Funds reported $3.97M of Regulus Therapeutics stock for Q1 2020, down 38% quarter-over-quarter.
- 6 funds opened new Regulus Therapeutics positions in Q1 2020 and 2 closed out, a net change of +4 holders.
- The largest Regulus Therapeutics buyer in Q1 2020 was EcoR1 Capital, an estimated $1.65M added.
- The largest Regulus Therapeutics seller in Q1 2020 was BVF Inc, an estimated $386K sold.
Based on aggregated 13F filings for Q1 2020.